These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 22723552)

  • 1. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
    Barreyro L; Will B; Bartholdy B; Zhou L; Todorova TI; Stanley RF; Ben-Neriah S; Montagna C; Parekh S; Pellagatti A; Boultwood J; Paietta E; Ketterling RP; Cripe L; Fernandez HF; Greenberg PL; Tallman MS; Steidl C; Mitsiades CS; Verma A; Steidl U
    Blood; 2012 Aug; 120(6):1290-8. PubMed ID: 22723552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
    Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
    Zhang Y; Park M; Ghoda LY; Zhao D; Valerio M; Nafie E; Gonzalez A; Ly K; Parcutela B; Choi H; Gong X; Chen F; Harada K; Chen Z; Nguyen LXT; Pichiorri F; Chen J; Song J; Forman SJ; Amanam I; Zhang B; Jin J; Williams JC; Marcucci G
    J Hematol Oncol; 2024 Aug; 17(1):67. PubMed ID: 39143574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis.
    De Boer B; Sheveleva S; Apelt K; Vellenga E; Mulder AB; Huls G; Jacob Schuringa J
    Haematologica; 2021 Dec; 106(12):3067-3078. PubMed ID: 33121233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
    Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
    Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL1RAP potentiates multiple oncogenic signaling pathways in AML.
    Mitchell K; Barreyro L; Todorova TI; Taylor SJ; Antony-Debré I; Narayanagari SR; Carvajal LA; Leite J; Piperdi Z; Pendurti G; Mantzaris I; Paietta E; Verma A; Gritsman K; Steidl U
    J Exp Med; 2018 Jun; 215(6):1709-1727. PubMed ID: 29773641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem and progenitor cell alterations in myelodysplastic syndromes.
    Shastri A; Will B; Steidl U; Verma A
    Blood; 2017 Mar; 129(12):1586-1594. PubMed ID: 28159737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
    Shastri A; Choudhary G; Teixeira M; Gordon-Mitchell S; Ramachandra N; Bernard L; Bhattacharyya S; Lopez R; Pradhan K; Giricz O; Ravipati G; Wong LF; Cole S; Bhagat TD; Feld J; Dhar Y; Bartenstein M; Thiruthuvanathan VJ; Wickrema A; Ye BH; Frank DA; Pellagatti A; Boultwood J; Zhou T; Kim Y; MacLeod AR; Epling-Burnette PK; Ye M; McCoon P; Woessner R; Steidl U; Will B; Verma A
    J Clin Invest; 2018 Dec; 128(12):5479-5488. PubMed ID: 30252677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
    Askmyr M; Ågerstam H; Hansen N; Gordon S; Arvanitakis A; Rissler M; Juliusson G; Richter J; Järås M; Fioretos T
    Blood; 2013 May; 121(18):3709-13. PubMed ID: 23479569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
    Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
    Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
    Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.